Pain in cancer survivors

Brown, Matthew; Ramirez, Juan D.; Farquhar-Smith, Paul

doi:10.1177/2049463714542605

Cited by 88 publications

(79 citation statements)

References 182 publications

(215 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…68 Radiotherapy may also increase fracture risk, particularly for pelvic fractures. 69 Lastly, incidence of 5-fluorouracil (5FU)-associated cardiotoxicity can occur in up to 68% of CRC CRC survivors 70 and may include angina-like chest pain, myocardial infarction, arrhythmias, heart failure, cardiogenic shock and sudden death.…”

Section: Colorectal Cancermentioning

confidence: 99%

Long-Term and Latent Side Effects of Specific Cancer Types

Gegechkori

Haines

Lin

2017

Medical Clinics of North America

218

128

View full text Add to dashboard Cite

Synopsis While many cancer survivors diagnosed with early-stage disease will outlive their cancer, they may continue to experience long-term and/or latent side effects due to cancer treatment. Many of these side effects are common and contribute to worse quality of life, morbidity and mortality for cancer survivors. We summarize the treatment side effects for several of the most prevalent cancers in the US.

show abstract

Section: Colorectal Cancermentioning

confidence: 99%

Long-Term and Latent Side Effects of Specific Cancer Types

Gegechkori

Haines

Lin

2017

Medical Clinics of North America

218

128

View full text Add to dashboard Cite

show abstract

“…The most common form of chronic pain in cancer survivors is neuropathic pain . This pain can last for months to years or even persist throughout a lifetime, with adverse impacts on functioning and quality of life . While nonopioid measures alone can often treat mild cancer‐related pain, opioids may be needed for treating more severe pain .…”

mentioning

confidence: 99%

“…4,5 This pain can last for months to years or even persist throughout a lifetime, 6 with adverse impacts on functioning and quality of life. [6][7][8] While nonopioid measures alone can often treat mild cancerrelated pain, opioids may be needed for treating more severe pain. 4,9,10 However, there have been growing concerns regarding long-term opioid therapy in older cancer survivors, in part due to the worsening epidemic of opioid toxicity in the United States.…”

mentioning

confidence: 99%

Long‐Term Opioid Therapy in Older Cancer Survivors: A Retrospective Cohort Study

Shah

Chou

Kuo

et al. 2019

J American Geriatrics Society

View full text Add to dashboard Cite

OBJECTIVES To examine the rates and predictors of long‐term opioid therapy in older cancer survivors. DESIGN Retrospective cohort study. SETTING Texas, United States. PARTICIPANTS Cancer survivors (5 years or more postcancer diagnosis) diagnosed from 1995 to 2008 and who were also Medicare Parts A, B, and D beneficiaries. MEASUREMENTS We used Medicare Part D event data to calculate the proportion of cancer survivors with a prolonged opioid prescription (90‐day or more supply of opioids/year). Adjusted odds ratios were calculated to identify predictors of prolonged opioid prescribing. All analyses were repeated with a subcohort of opioid‐naïve cancer survivors. RESULTS The rate of prolonged opioid therapy for cancer patients diagnosed in 2008 was 7.1% prior to cancer diagnosis; it rose to 9.8% within a year of cancer treatments, and to 13.3% at 5 years postdiagnosis. The rate at the sixth year varied by cancer sites: 19.4% in lung cancer and 9.6% in prostate cancer. Among opioid‐naïve survivors, the rate increased from 1.4% to 7.1%, from 5 to 18 years postcancer diagnosis. Cancer survivors diagnosed in 2004 to 2008 had higher rates of opioid prescribing compared to those diagnosed in 1995 to 1998 and 1999 to 2003. Years since diagnosis, a later year of diagnosis, female sex, urban location, lung cancer diagnosis, disability as reason for Medicare entitlement, Medicaid eligibility, one or more comorbidity, and history of depression or drug abuse were predictors of prolonged opioid therapy. Among opioid‐naïve cancer survivors, diagnosis in 2004 to 2008 was the strongest predictor, while a history of drug abuse was the strongest predictor for all the survivors. CONCLUSION The rates of prolonged opioid prescribing for older cancer survivors remained high at 5 or more years after cancer diagnosis. Our findings have potential to inform the development of clinical guidelines and public policy to ensure safer and more effective pain treatment in older cancer survivors. J Am Geriatr Soc 67:945–952, 2019.

show abstract

“…Most of the side effects can be prevented except the chemotherapy-induced peripheral neuropathy (CIPN). CIPN, varying from 30 to 70% of patients receiving chemotherapy, leads to poor quality of life and discontinuation of useful anti-cancer treatment4. For example, paclitaxel is one of commonly used chemotherapeutic agents for the treatment of breast, lung and ovarian cancers56.…”

mentioning

confidence: 99%

Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy

Chen

Yeh

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of cancer treatment. No medication has been shown to be effective in the treatment of CIPN. This study aims to integrate the image-based high-content screening, mouse behavior models and mechanistic cell-based assays to discover potential neuroprotective drugs. Among screened compounds, minoxidil showed the most potent neuroprotective effect against paclitaxel, with regard to neurite outgrowth of dorsal root ganglia (DRG). Minoxidil protected mice from thermal insensitivity and alleviated mechanical allodynia in paclitaxel-treated mice. The ultrastructure and quantified G-ratio of myelin integrity of sciatic nerve tissues supported the observations in mouse behavioral tests. The mechanistic study on DRG neurons suggested that minoxidil suppressed neuroinflammation and remodeled the dysregulation of intracellular calcium homeostasis provoked by paclitaxel. Importantly, minoxidil showed a synergistic anti-tumor effect with paclitaxel both in tumor xenograft models of cervical and breast cancer. Interestingly, the quantitative assays on hair length and hair growth both exhibited that minoxidil significantly improved the hair quality after chemotherapy. Since minoxidil is a drug approved by the Food and Drug Administration (FDA), the safety and biocompatibility are well documented. The immediate next step is to launch an early-stage clinical trial intending to prevent CIPN by minoxidil.

show abstract

Pain in cancer survivors

Cited by 88 publications

References 182 publications

Long-Term and Latent Side Effects of Specific Cancer Types

Long-Term and Latent Side Effects of Specific Cancer Types

Long‐Term Opioid Therapy in Older Cancer Survivors: A Retrospective Cohort Study

Minoxidil is a potential neuroprotective drug for paclitaxel-induced peripheral neuropathy

Contact Info

Product

Resources

About